Author:
Cassileth P A,Cheuvart B,Spiers A S,Harrington D P,Cummings F J,Neiman R S,Bennett J M,O'Connell M J
Abstract
Fifty patients with hairy cell leukemia were treated with pentostatin (2'-deoxycoformycin; dCF) for a median of 3 months; 32 (64%) patients achieved complete remission (CR), and 10 (20%) patients achieved partial remission (PR), for an overall response rate of 84%. After reaching maximal response, no maintenance therapy was administered. The median duration of follow-up is now 39 months, and only four of 32 patients in CR and two of 10 patients in PR have relapsed. dCF therapy produces durable long-term, disease-free survival in patients with hairy cell leukemia.
Publisher
American Society of Clinical Oncology (ASCO)
Cited by
92 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses;Scientific Reports;2024-08-21
2. Cancers of the Blood;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13
3. Homopurine Alkaloids: A Brief Overview;Natural Product Communications;2020-04
4. Hairy Cell Leukemia;Abeloff's Clinical Oncology;2020
5. Hairy Cell Leukemia;Neoplastic Diseases of the Blood;2017-09-09